Last reviewed · How we verify
Elrexfio (elranatamab)
Bispecific antibody binding BCMA on myeloma cells and CD3 on T-cells, causing cytolysis.
Elranatamab-bcmm (ELREXFIO) is a bispecific BCMA-directed T-cell engager approved under accelerated approval for relapsed or refractory multiple myeloma after ≥4 prior lines of therapy. The drug demonstrates dose-proportional pharmacokinetics with a 22-day half-life and 56.2% subcutaneous bioavailability, achieving steady-state exposure by week 48 on biweekly dosing. Key risks include cytokine release syndrome and increased CYP substrate exposure requiring monitoring of narrow-index drugs. Continued approval is contingent upon verification of clinical benefit in confirmatory trials.
At a glance
| Generic name | elranatamab |
|---|---|
| Sponsor | Pfizer |
| Drug class | Bispecific antibody |
| Target | BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2023 |
| Annual revenue | 304 |
Mechanism of action
Elranatamab-bcmm is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody that functions as a bridge between BCMA-expressing multiple myeloma cells and CD3-expressing T-cells. By binding simultaneously to both targets, the drug brings T-cells into close proximity with myeloma cells, leading to T-cell activation and cytolysis of BCMA-expressing cells. The mechanism involves activation of T-cells, proinflammatory cytokine release, and subsequent multiple myeloma cell lysis.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Neutropenia
- Anaemia
- Diarrhoea
- Cytokine release syndrome
- Pyrexia
- Leukopenia
- Fatigue
- Thrombocytopenia
- Hypokalaemia
- Hypogammaglobulinaemia
- Decreased appetite
- Nausea
Drug interactions
- CYP substrates (particularly those with narrow therapeutic index)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elrexfio CI brief — competitive landscape report
- Elrexfio updates RSS · CI watch RSS
- Pfizer portfolio CI